Zoledronic Acid + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Osteopenia

Conditions

Osteopenia

Trial Timeline

Jul 1, 2004 → Feb 1, 2008

NCT ID

NCT00132808

About Zoledronic Acid + Placebo

Zoledronic Acid + Placebo is a phase 3 stage product being developed by Novartis for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00132808. Target conditions include Osteopenia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01788176	Phase 2	UNKNOWN	Dec 1, 2013	Dec 1, 2016	Complex Regional Pain Syndromes
NCT01702415	Approved	Withdrawn	Oct 1, 2013	Dec 1, 2015	Cystic Fibrosis
NCT01166178	Phase 3	Terminated	Oct 1, 2010	Jun 1, 2012	Osteoporosis
NCT00844480	Phase 2	Terminated	Mar 1, 2010	Jan 1, 2016	Bone Loss
NCT01016093	Phase 2/3	UNKNOWN	Nov 1, 2009	Dec 1, 2011	Beta-Thalassemia
NCT00781261	Phase 2	UNKNOWN	Aug 1, 2009	Dec 1, 2013	Osteonecrosis
NCT00799266	Phase 3	Completed	Dec 4, 2008	Mar 5, 2018	Osteoporosis
NCT00333229	Approved	Terminated	Mar 1, 2006	Dec 1, 2013	Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
NCT00320710	Phase 3	Completed	Feb 1, 2006	Jul 1, 2013	Breast Cancer
NCT00375505	Phase 3	Completed	Oct 1, 2005	May 1, 2014	Breast Cancer
NCT00145327	Phase 3	Completed	May 1, 2005	Nov 1, 2009	Osteoporosis
NCT00132808	Phase 3	Completed	Jul 1, 2004	Feb 1, 2008	Osteopenia

Competing Products

18 competing products in Osteopenia

See all competitors

Product	Company	Stage	Hype Score
Teriparatide + Zoledronic Acid	Eli Lilly	Approved	85
alendronate sodium	Merck	Approved	85
zoledronic acid	Novartis	Phase 3	77
zoledronic acid vs pamidronate	Novartis	Approved	85
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804	Novartis	Phase 2	52
Placebo + ibandronate [Bonviva/Boniva]	Roche	Approved	85
ibandronate [Bonviva/Boniva] + Placebo	Roche	Phase 3	77
Romosozumab + Placebo	Amgen	Phase 1	32
Placebo + AMG 167	Amgen	Phase 1	32
AMG 167 + Placebo	Amgen	Phase 1	32
Romosozumab + Placebo	Amgen	Phase 1	32
Denosumab	Amgen	Phase 3	76
Romosozumab + Placebo	Amgen	Phase 1	32
Dasatinib 100 Mg Oral Tablet	Novo Nordisk	Phase 2	51
RN564	Pfizer	Phase 1	32
risedronate + alendronate	Sanofi	Phase 1	32
Menostar (Estradiol, BAY86-5435) + Raloxifene	Bayer	Phase 3	74
tibolone + raloxifen	Organon	Approved	80

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved